Viking Therapeutics Shares Rise on Positive Obesity Drug Data; Rivals See Decline
Shares of Viking Therapeutics (VKTX) surged Tuesday following positive clinical trial results for its weight-loss drug, VK2735. The study showed that patients using the every-other-week and monthly dosing schedules maintained nearly all their initial weight loss over three months after starting on a weekly dose. This promising data fueled optimism about the drug's potential in the competitive obesity treatment market. The positive news for Viking Therapeutics came at the expense of its major rivals, Eli Lilly (LLY) and Novo Nordisk (NVO), whose shares declined as investors shifted focus to Viking’s progress. The results highlight growing interest in alternative dosing regimens that could improve patient compliance while maintaining efficacy. The obesity drug market remains a key battleground for pharmaceutical companies seeking long-term revenue streams, with new data often triggering significant stock movements.
Topics: clinical trial results stock movement weight-loss drug